Tesamorelin and sermorelin both stimulate growth hormone release, but their safety profiles are not identical. Tesamorelin has FDA-reviewed trial data for HIV-associated lipodystrophy and commonly causes injection-site reactions, while sermorelin is used off-label in adults through compounding pharmacies and has less robust adult safety evidence 1.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What is the quick answer on sermorelin vs tesamorelin side effects?
Sermorelin vs tesamorelin side effects is not a simple “which is safer” question. Tesamorelin has more FDA-reviewed human data for one approved use, while sermorelin has a shorter-acting, more physiologic reputation but weaker adult evidence.
For patients, the bottom line is this: tesamorelin’s risks are better described in trials and labeling, especially injection-site reactions, glucose intolerance, fluid retention, arthralgia, myalgia, and IGF-1 increases 1. Sermorelin can share class-related effects because it also stimulates the pituitary gland to release human growth hormone, but adult use is off-label and requires monitoring rather than assumptions 3.
The bottom line for patients comparing safety
Tesamorelin may look “more serious” because its label lists detailed trial adverse events. Sermorelin may look “milder” because there is less modern adult trial data. Neither view is complete. A licensed clinician should review diabetes risk, active malignancy history, cardiovascular history, edema, carpal-tunnel-like symptoms, and baseline labs before either peptide is considered 2.
How are sermorelin and tesamorelin different?
Sermorelin and tesamorelin are both growth hormone-releasing hormone analogs, also called GHRH analogs or growth hormone secretagogues. The key difference is that tesamorelin is an FDA-approved drug for a narrow HIV-related indication, while sermorelin is used in adults off-label when prescribed.
Sermorelin: a GHRH 1-29 analog that stimulates pituitary growth hormone release
Sermorelin is the 29-amino-acid active fragment of growth hormone-releasing hormone. It binds the GHRH receptor at the pituitary gland and stimulates the body’s own pulsatile growth hormone release, which can then increase downstream IGF-1 signaling 4.
Geref, a sermorelin product, was previously approved for diagnosing and treating growth hormone deficiency in children, but it was discontinued and is not currently marketed as an FDA-approved adult longevity, body-composition, or weight-loss drug 3.
Tesamorelin: a modified GHRH analog with FDA approval for HIV-associated lipodystrophy
Tesamorelin is a modified 44-amino-acid growth hormone-releasing factor analog. Egrifta SV and Egrifta WR are FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a condition involving abnormal fat distribution in some people living with HIV 2.
In the FDA-reviewed evidence base, tesamorelin reduced visceral adipose tissue, or visceral fat, in adults with HIV-associated lipodystrophy, but the clinical review also noted limits in study methods and missing-data handling 1. That evidence should not be stretched into a general weight-loss or longevity claim.
Why potency, half-life, and indication matter for side effects
A longer-acting or more sustained GHRH signal can mean more noticeable growth hormone and IGF-1 effects. That is why the same pathway that may change body composition can also cause swelling, joint symptoms, glucose changes, or carpal-tunnel-like symptoms in some patients 2.
| Feature | Sermorelin | Tesamorelin |
|---|---|---|
| Drug class | GHRH 1-29 analog; growth hormone secretagogue | Modified GHRH/GHRF analog; growth hormone secretagogue |
| Main mechanism | Stimulates pituitary growth hormone release and downstream IGF-1 signaling | Stimulates pituitary growth hormone release and downstream IGF-1 signaling |
| FDA status | Former pediatric product Geref discontinued; no current FDA-approved adult longevity, weight-loss, or body-composition indication | FDA-approved as Egrifta products for reducing excess abdominal fat in adults with HIV-associated lipodystrophy |
| Evidence strength | Less robust modern adult outcome data | Randomized, placebo-controlled human trials for HIV-associated lipodystrophy |
| Chia availability | Sermorelin is offered as injection, nasal spray, and tablets | Chia does not list tesamorelin as a current treatment |
Which side effects do sermorelin and tesamorelin share?
Both peptides can cause effects linked to injections and growth hormone signaling. The most relevant shared risks are injection-site reactions, headache, flushing, swelling, joint pain, muscle aches, and changes in growth hormone or IGF-1 activity.
Injection-site reactions
Injection-site reactions can include redness, itching, pain, swelling, or irritation. In tesamorelin trials, injection-site reactions were among the most common adverse events listed in FDA labeling 2. Sermorelin injections can also irritate the skin because any injected peptide can cause local reactions.
Headache, flushing, swelling, or fluid retention
Growth hormone signaling can affect fluid balance. Tesamorelin labeling lists edema and fluid-retention-related symptoms, and sermorelin may cause similar class-related symptoms in susceptible patients 2. Patients with swelling, shortness of breath, or rapid weight changes should be evaluated promptly.
Joint pain, muscle aches, and carpal-tunnel-like symptoms
Arthralgia means joint pain, and myalgia means muscle aches. These symptoms can happen when growth hormone or IGF-1 signaling increases fluid retention in soft tissues; tesamorelin labeling includes musculoskeletal adverse reactions and carpal tunnel syndrome among clinically relevant events 2.
Changes in growth hormone and IGF-1 signaling
IGF-1 is insulin-like growth factor 1, a hormone signal made mainly in the liver after growth hormone stimulation. Tesamorelin labeling warns that IGF-1 can rise and recommends monitoring in certain patients because sustained high IGF-1 may matter clinically 2.
What side effects are more important with tesamorelin?
Tesamorelin side effects deserve close attention because the medication has a defined FDA label, a studied dose form, and specific warnings. The clearest concerns are injection-site reactions, glucose changes, fluid retention, joint symptoms, and recurrence of visceral fat after stopping.
Injection-site reactions in clinical trials
In FDA labeling for Egrifta SV, injection-site reactions were common enough to be highlighted in the adverse-reaction section 2. These reactions are usually local, but patients should still report severe rash, hives, or signs of allergy.
Blood sugar and diabetes-related monitoring
Tesamorelin can affect glucose metabolism. The FDA label warns about glucose intolerance and diabetes risk, so patients with diabetes, prediabetes, or strong metabolic risk factors need careful clinician review before and during therapy 2.
Fluid retention and joint symptoms
Fluid retention can show up as swelling, stiffness, joint pain, or numbness and tingling that resembles carpal tunnel syndrome. These effects are biologically plausible because tesamorelin increases growth hormone and IGF-1 activity 2.
What happens when tesamorelin is stopped
Tesamorelin’s FDA-approved effect is not permanent. In pivotal studies, visceral adipose tissue increased again after tesamorelin was stopped, meaning the studied effect on HIV-associated visceral fat was treatment-dependent 5. Individual results vary.
What are the possible dangers of taking sermorelin?
Sermorelin dangers are mostly about using a growth hormone–releasing peptide without enough evaluation or monitoring. Adult use is off-label, so safety depends on patient selection, lab follow-up, prescription source, and the quality of the compounding pharmacy.
Off-label adult use and evidence limits
Sermorelin is not currently FDA-approved for adult longevity, muscle gain, body composition, or weight loss. Older clinical research supports its ability to stimulate growth hormone release, but that is not the same as proving long-term adult outcomes for wellness or aging goals 6.
Why IGF-1 monitoring may matter
Because sermorelin works upstream of growth hormone, monitoring may include IGF-1 and symptom review. Too much growth hormone signaling can be linked with swelling, joint pain, glucose changes, or carpal-tunnel-like symptoms, so follow-up is part of safe use 7.
Who may not be a good candidate for growth hormone–releasing peptides
People with active malignancy, unexplained symptoms, uncontrolled diabetes, untreated severe sleep apnea, significant edema, or complex cardiovascular history may need extra caution or may not be candidates. Tesamorelin labeling specifically lists active malignancy as a contraindication, reflecting a broader concern with growth hormone and IGF-1 signaling in cancer biology 2.
Why compounded medications require clinician oversight
The safety divide is not “internet peptide versus brand name.” It is licensed care versus unlicensed sourcing. A legitimate compounded sermorelin path should include a prescription from a licensed clinician, a state-licensed 503A compounding pharmacy, clear follow-up, and a way to report side effects.
3-min quiz
Considering sermorelin with clinician guidance?
At Chia, sermorelin is available as injection, nasal spray, and tablets when a licensed US provider decides it is clinically appropriate. Treatment starts with an online health questionnaire and clinician review; a prescription is not guaranteed. Chia medications are compounded in the US by state-licensed 503A pharmacies, and compounded medications are not FDA-approved.
Is tesamorelin safer than sermorelin?
Tesamorelin is not automatically safer, and sermorelin is not automatically gentler for every patient. Tesamorelin has stronger FDA-reviewed evidence for one condition, while sermorelin’s adult use has more uncertainty and depends heavily on clinical oversight.
| Safety question | Sermorelin | Tesamorelin |
|---|---|---|
| FDA-reviewed indication | No current FDA-approved adult longevity, body-composition, or weight-loss indication | Approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy |
| Human evidence | Evidence supports GH stimulation, but adult wellness outcome data are limited | Randomized, placebo-controlled trials for HIV-associated lipodystrophy |
| Common side effects | Injection-site irritation, headache, flushing, swelling, joint or muscle symptoms | Injection-site reactions, rash, swelling, joint pain, muscle aches, glucose changes |
| Monitoring focus | Symptoms, IGF-1 when appropriate, glucose risk, medical history review | IGF-1, glucose/diabetes risk, malignancy history, fluid-retention symptoms |
| Weight-loss role | Not proven as a routine weight-loss or GLP-1 add-on | Not indicated for general weight-loss management |
Why FDA-reviewed evidence does not mean risk-free
FDA approval means tesamorelin was reviewed for a specific use, dose form, and patient group. It does not mean the medication is risk-free, and it does not mean the evidence applies to people without HIV-associated lipodystrophy 2.
Why a milder reputation does not prove sermorelin is safer for every patient
Sermorelin is often described as more physiologic because it asks the pituitary to release growth hormone rather than replacing human growth hormone directly. But a plausible mechanism is not a safety guarantee, especially when adult use is off-label and modern long-term outcome trials are limited 6.
Sermorelin at Chia: injections, nasal spray, or tablets
At Chia, we offer sermorelin as injections, nasal spray, and tablets through a 100% online, clinician-reviewed process. Plans currently start at $179/mo for sermorelin injection or nasal spray; see the product page for current details.
What Chia offers for sermorelin
| Chia sermorelin form | How it may fit a patient’s life | Current starting price listed |
|---|---|---|
| Injection | For patients comfortable with injections and clinician-guided follow-up | From $179/mo |
| Nasal spray | For patients who prefer a non-injection option when clinically appropriate | From $179/mo |
| Tablets | For patients who prefer an oral option when clinically appropriate | See product page |
How online clinician review works
Treatment starts with a short online health questionnaire, then a licensed US provider reviews medical history, goals, medications, and safety factors. If prescribed, medication is compounded by a state-licensed 503A pharmacy and shipped to the patient’s door.
How provider-guided dosing and follow-up work
We do not give one-size-fits-all dosing instructions in articles. If a Chia provider prescribes sermorelin, dosing and follow-up are provider-guided and adjusted over time. Patients can message their care team through the patient portal between visits.
Important note: Chia does not list tesamorelin as a current treatment
Chia’s live catalog includes sermorelin, Foundation Longevity, and Weight + Muscle protocols that may include sermorelin. Chia does not list tesamorelin as a current treatment.
Can sermorelin or tesamorelin be used for weight loss?
Neither peptide is a primary weight-loss medication. Tesamorelin is approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and sermorelin does not have strong clinical evidence as a routine weight-loss drug or GLP-1 add-on.
Why neither peptide is a primary weight-loss medication
A medicine can change visceral fat without causing broad weight loss on the scale. Tesamorelin labeling states it is not indicated for weight-loss management, and its approved use is limited to HIV-associated lipodystrophy 2.
Tesamorelin evidence for visceral fat in HIV-associated lipodystrophy
In a randomized trial published in The New England Journal of Medicine, tesamorelin reduced visceral adipose tissue in patients with HIV-associated abdominal fat accumulation, with adverse events and metabolic monitoring remaining important parts of care 5. Individual results vary.
Evidence limits for sermorelin as a weight-loss or GLP-1 add-on
Sermorelin is sometimes discussed alongside GLP-1 medications, but available evidence does not establish it as a routine add-on for greater weight loss, visceral fat reduction, or muscle preservation. That is why we frame sermorelin as a growth hormone–axis peptide, not a substitute for evidence-based obesity medication.
When GLP-1 medications may be the more evidence-based weight-loss path
For patients whose main goal is weight management, GLP-1 or dual incretin medications such as semaglutide or tirzepatide have dedicated obesity clinical trial programs and FDA-approved branded products for chronic weight management 8. Chia offers compounded semaglutide and tirzepatide through licensed-provider evaluation; compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.
What should patients ask a clinician before using either peptide?
Before using either peptide, ask about your personal risks, what labs matter, what symptoms should trigger follow-up, and where the medication comes from. This is especially important for growth hormone–releasing peptides because they affect hormone signaling across several tissues.
- What is the specific goal of treatment, and is that goal supported by human evidence for this peptide?
- Do I have diabetes, prediabetes, edema, sleep apnea, cancer history, or cardiovascular risk factors that change the safety picture?
- Should baseline IGF-1, fasting glucose, A1c, lipids, or other labs be checked before or during treatment?
- What side effects should I report right away, such as swelling, numbness, joint pain, rash, or high blood sugar symptoms?
- Is the medication prescribed by a licensed clinician and dispensed by a state-licensed 503A compounding pharmacy?
- If I am using a GLP-1 medication, is there evidence for the combination in patients like me, or is the peptide being used for a different goal?
If you want Chia to review whether sermorelin fits your goals, you can start with the online eligibility quiz. Our providers review each case and prescribe only when clinically appropriate.
3-min quiz
Start a clinician-reviewed sermorelin visit
Chia offers sermorelin as injection, nasal spray, and tablets, with provider-guided dosing and follow-up when prescribed. A licensed provider must review your health history first, and a prescription is never guaranteed. Compounded medications are not FDA-approved.
FAQ: sermorelin vs tesamorelin side effects
There is no universal answer. Tesamorelin has more FDA-reviewed human safety data for HIV-associated lipodystrophy, while sermorelin adult use is off-label and has less robust adult outcome evidence. The safer option depends on your medical history, labs, goals, and clinician review.
Important tesamorelin risks include injection-site reactions, rash or allergy, swelling, joint pain, muscle aches, carpal-tunnel-like symptoms, glucose intolerance, diabetes-related concerns, increased IGF-1, and concern in people with active malignancy.
Sermorelin can cause injection-site irritation, headache, flushing, dizziness, swelling, joint or muscle symptoms, and possible IGF-1 changes. Adult use is off-label, so clinician oversight and follow-up are important.
In clinical studies, the reduction in visceral fat was not permanent after stopping tesamorelin. Visceral fat tended to increase again after treatment stopped, so patients should not assume lasting body-composition changes.
Sermorelin was previously marketed as Geref for pediatric growth hormone deficiency, but it is not currently FDA-approved for adult longevity, body composition, or weight loss. Adult use is off-label when prescribed.
Yes. Tesamorelin products in the Egrifta family are FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Tesamorelin is not a general weight-loss medication.
No. Chia does not list tesamorelin as a current treatment in the live catalog.
Yes. Chia offers compounded sermorelin as injections, nasal spray, and tablets when a licensed provider determines it is clinically appropriate. A prescription is never guaranteed, and compounded medications are not FDA-approved.
References
- 1.CADTH Common Drug Review. Clinical Review Report: Tesamorelin (Egrifta) — Results. Canadian Agency for Drugs and Technologies in Health, 2016.
- 2.Theratechnologies. EGRIFTA SV (tesamorelin) for injection, prescribing information. U.S. Food and Drug Administration, 2024.
- 3.EMD Serono. GEREF (sermorelin acetate) injection, prescribing information. U.S. Food and Drug Administration, 2007.
- 4.Mayo KE, Miller T, DeAlmeida V, et al. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology, 1992.
- 5.Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007.
- 6.Thorner MO, Vance ML, Horvath E, et al. The anterior pituitary. In: Williams Textbook of Endocrinology; clinical studies of growth hormone-releasing hormone and sermorelin physiology. Endocrine Reviews, 1986.
- 7.Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2011.
- 8.U.S. Food and Drug Administration. WEGOVY (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
